Medullary carcinoma of the breast: a brief report from a tertiary care center.

for those without LNM were 68.7–80.2%, whereas for patients with LNM not receiving chemotherapy this ratio was 44.4%–50.0% [3]. Metastasis, as demonstrated in our analysis is rare in this subtype. In addition, a recent study has also shown that ER positivity is infrequent, and that there are racial disparities in survival. Moreover, it has been shown that inadequate lymphadenectomy may lead to understaging, as the survival increases with increasing lymph node yield [4]. Furthermore, Pinto et al. reported no survival difference between ER+ and ER- patients, suggesting hormone therapy resistance [5]. To conclude, medullary breast carcinoma has unique characteristics of its own which need to be taken into consideration during diagnosis and selection of treatment modalities. In this study we presented a brief report of our experience and a concise summary of the current information about this uncommon pathology.

[1]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[2]  E. Winer,et al.  A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Bold,et al.  Medullary carcinoma of the breast: a population-based perspective , 2011, Medical oncology.

[4]  E. Perez,et al.  5001 ORAL Trastuzumab Emtansine (T-DM1) Vs Trastuzumab Plus Docetaxel (H+T) in Previously-untreated HER2-positive Metastatic Breast Cancer (MBC): Primary Results of a Randomized, Multicenter, Open-label Phase II Study (TDM4450g/BO21976) , 2011 .

[5]  H. Rugo,et al.  Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Trifiro,et al.  Hormonal manipulation of benign metastasizing leiomyomas: report of two cases and review of the literature. , 2004, The Journal of clinical endocrinology and metabolism.

[7]  C. Hudis,et al.  Cardiac dysfunction in the trastuzumab clinical trials experience. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Soares,et al.  C-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  M. Burt,et al.  REGRESSION OF UTERINE LOW‐GRADE SMOOTH‐MUSCLE TUMORS METASTATIC TO THE LUNG AFTER OOPHORECTOMY , 1997, Obstetrics and gynecology.

[10]  E. Gunel,et al.  Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  D. Delbeke,et al.  Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy. , 1996, Chest.

[12]  B. Fisher,et al.  Medullary cancer of the breast revisited , 1990, Breast Cancer Research and Treatment.

[13]  P. Rosen,et al.  Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. , 1977, Cancer.